Mattila Kalle E, Tiainen Leena, Vikkula Johanna, Kreutzman Anna, Engström-Risku Mia, Kysenius Kai, Hölsä Olivia, Hernesniemi Sari, Hemmilä Päivikki, Pystynen Anssi, Mäkelä Siru
Department of Oncology & Radiotherapy & Fican West Cancer Centre, University of Turku and Turku University Hospital, Turku, Finland.
InFLAMES Research Flagship Center, University of Turku, Turku, Finland.
Future Oncol. 2024 Dec;20(40):3491-3505. doi: 10.1080/14796694.2024.2403329. Epub 2024 Sep 30.
First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT). Retrospective cohort study of real-world patients treated with 1L immunotherapy (144 wild type, 85 -mutated) or 1L TT (143 -mutated) for MM in Finland during 2014-2021. Baseline brain metastases, liver metastases and elevated LDH were less common, 2-year OS rates were higher (60.3-63.5% vs. 33.8%) and more patients were alive without the next-line treatment (38.0-43.8% vs. 23.3%) in patients with 1L immunotherapy. Real-world patients with 1L immunotherapy for MM had favorable baseline characteristics and better treatment outcomes than observed in patients with 1L TT.
一线（1L）免疫疗法已在转移性黑色素瘤（MM）中产生了更高的总生存期（OS），但一些患者不符合免疫疗法的条件，或者需要通过一线靶向治疗（TT）获得快速反应。对2014年至2021年期间在芬兰接受1L免疫疗法（144例野生型，85例突变型）或1L TT（143例突变型）治疗MM的真实世界患者进行回顾性队列研究。基线脑转移、肝转移和乳酸脱氢酶升高的情况较少见，1L免疫疗法患者的2年总生存率更高（60.3-63.5%对33.8%），且更多患者在未接受二线治疗的情况下存活（38.0-43.8%对23.3%）。接受1L免疫疗法治疗MM的真实世界患者具有良好的基线特征，且治疗结果优于接受1L TT的患者。
